Biotech company Nouscom has appointed Marina Udier as Chief Executive Officer and Patricia Delaite as Chief Medical Officer. Patricia Delaite joins from AMAL Therapeutics. And former Foundation Medicine CEO Troy Cox has been elected as Chairman of the Board of Directors of Sophia Genetics.
In a mature startup ecosystem experienced insiders are changing their roles and team members of acquired start-ups join new companies to help them scaling up. This is exactly what happens in the Swiss life sciences sector.
Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that it has appointed Marina Udier, PhD, as Chief Executive Officer (CEO) and Patricia Delaite, MD, as Chief Medical Officer (CMO) with immediate effect.
Marina Udier joined Nouscom as Chief Operating Officer (COO) in 2016 from investment firm Versant Ventures and was appointed interim CEO in May 2019 upon the retirement of former CEO and founder Dr. Alfredo Nicosia. Prior to Versant, she held senior development and commercial roles at Novartis in Basel. Previously, Dr. Udier worked for McKinsey & Company in the US. She has a Ph.D. in Organic Chemistry from Yale University.
Patricia Delaite, MD, joins from the well-known Swiss biotech start-up AMAL Therapeutics, which was acquired by Boehringer Ingelheim last year, where she was CMO and a key member of the Senior Executive Team. At AMAL, Dr. Delaite designed and implemented a First-in-Human therapeutic cancer vaccine trial enabling innovative proof-of-concept endorsed by clinical experts and regulators at agencies in the US and Europe.
Former Foundation Medicine CEO Troy Cox has been elected as Chairman of the Board of Directors of Sophia Genetics, effective March 1, 2020. Cox joined the company in July of 2019 as a member of the board. A healthcare industry visionary leader, Troy Cox formerly served as CEO of Foundation Medicine (FMI), where his work was recognized by the acquisition of the company by Roche in 2018. Roche first bought a 56 percent stake in FMI for $1 billion in 2015 and acquired the rest of the company for$2.4 billion. Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.
Pictures: Marina Udier, Patricia Delaite, Troy Cox (from left)
0Comments
Please login or sign up to comment.
Commenting guidelines